Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

FDA green lights BMS’ multiple myeloma combo

FDA green lights BMS’ multiple myeloma combo That particular regimen also includes corticosteroid medication dexamethasone and Celgene’s blockbuster Revlimid, which generated around $8bn in sales last year.

FDA clears first-line use for J&J’s myeloma drug Darzalex

FDA clears first-line use for J&J’s myeloma drug Darzalex Later on, additional studies of Darzalex as an add-on to regimens based on Celgene’s Revlimid (lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated

Celgene to launch five new products through to 2020

Celgene to launch five new products through to 2020 The statements came as Celgene reported expectation-topping sales and earnings driven by Revlimid (lenalidomide) and new psoriasis therapy Otezla (apremilast). ... For comparison, Revlimid sales are expected to come in at around $9.7bn this year.

Chinese biotech’s global ambitions

Chinese biotech’s global ambitions Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market

Geron poleaxed as partner J&J abandons only pipeline drug

Geron poleaxed as partner J&J abandons only pipeline drug s broad portfolio headed by Revlimid (lenalidomide), and a clutch of new candidates coming through mid- to late-stage clinical development.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics